Compare Gilead Sciences, Inc. (GILD) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.38. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| GILD | YMAG | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $15.98 |
52-Week Low | $110.56 | $10.76 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.58, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.07 to $0.40 per share. News highlights ongoing distribution announcements and analysis of its option income strategy, though key financial ratios are not provided in the data.
The outlook hinges on YMAG's ability to sustain high distributions through its option strategy, but earnings volatility in underlying holdings poses a risk to NAV stability. Investor sentiment is mixed, with some analysts viewing it as a tactical buy in rangebound markets, while others caution on compounded decay across its seven underlying ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
